Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas

Peter W T Pisters, Shreyaskumar R. Patel, Victor G. Prieto, Peter F. Thall, Valerae O. Lewis, Barry W. Feig, Kelly K. Hunt, Alan W. Yasko, Patrick P. Lin, Marc G. Jacobson, Michael A. Burgess, Raphael E. Pollock, Gunar K. Zagars, Robert S. Benjamin, Matthew Ballo

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Purpose: The primary objective of this phase I trial was to define the maximum-tolerated dose of continuous-infusion doxorubicin administered with standard preoperative radiation for patients with localized, potentially resectable soft tissue sarcomas of the extremities or body wall. Patients and Methods: Twenty-seven patients with radiographically resectable intermediate- or high-grade soft tissue sarcomas were treated. Preoperative external-beam radiation was administered in 25 2-Gy fractions (total dose, 50 Gy). Concurrent continuous-infusion doxorubicin was administered by an initial bolus (4 mg/m2) and subsequent 4-day continuous infusion (12.5, 15.0, 17.5, or 20.0 mg/m2/wk). Radiographic restaging was performed 4 to 7 weeks after chemoradiation, and patients with localized disease underwent surgical resection. Results: Chemoradiation was completed as an outpatient procedure in 25 patients (93%). The maximum-tolerated dose of continuous-infusion doxorubicin combined with standard preoperative radiation was 17.5 mg/m2/wk; at this dose level, seven (30%) of 23 patients had grade 3 dermatologic toxicity. Macroscopically complete resection (R0 or R1) was performed in all 26 patients who underwent surgery. Among 22 patients who were treated with doxorubicin 17.5/mg/m2/wk with concurrent radiation and subsequent surgery, 11 patients (50%) had 90% or greater tumor necrosis, including two patients who had complete pathologic responses. Conclusion: Preoperative doxorubicin-based chemoradiation appears safe and feasible. The maximum-tolerated dose of continuous-infusion doxorubicin with standard preoperative radiation was 17.5 mg/m2/wk. Pathologic response rates with this regimen are encouraging.

Original languageEnglish (US)
Pages (from-to)3375-3380
Number of pages6
JournalJournal of Clinical Oncology
Volume22
Issue number16
DOIs
StatePublished - Dec 1 2004
Externally publishedYes

Fingerprint

Sarcoma
Doxorubicin
Extremities
Maximum Tolerated Dose
Radiation
Necrosis
Outpatients

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas. / Pisters, Peter W T; Patel, Shreyaskumar R.; Prieto, Victor G.; Thall, Peter F.; Lewis, Valerae O.; Feig, Barry W.; Hunt, Kelly K.; Yasko, Alan W.; Lin, Patrick P.; Jacobson, Marc G.; Burgess, Michael A.; Pollock, Raphael E.; Zagars, Gunar K.; Benjamin, Robert S.; Ballo, Matthew.

In: Journal of Clinical Oncology, Vol. 22, No. 16, 01.12.2004, p. 3375-3380.

Research output: Contribution to journalArticle

Pisters, PWT, Patel, SR, Prieto, VG, Thall, PF, Lewis, VO, Feig, BW, Hunt, KK, Yasko, AW, Lin, PP, Jacobson, MG, Burgess, MA, Pollock, RE, Zagars, GK, Benjamin, RS & Ballo, M 2004, 'Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas', Journal of Clinical Oncology, vol. 22, no. 16, pp. 3375-3380. https://doi.org/10.1200/JCO.2004.01.040
Pisters, Peter W T ; Patel, Shreyaskumar R. ; Prieto, Victor G. ; Thall, Peter F. ; Lewis, Valerae O. ; Feig, Barry W. ; Hunt, Kelly K. ; Yasko, Alan W. ; Lin, Patrick P. ; Jacobson, Marc G. ; Burgess, Michael A. ; Pollock, Raphael E. ; Zagars, Gunar K. ; Benjamin, Robert S. ; Ballo, Matthew. / Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas. In: Journal of Clinical Oncology. 2004 ; Vol. 22, No. 16. pp. 3375-3380.
@article{9efd6ae1231845dab852a0e31301969d,
title = "Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas",
abstract = "Purpose: The primary objective of this phase I trial was to define the maximum-tolerated dose of continuous-infusion doxorubicin administered with standard preoperative radiation for patients with localized, potentially resectable soft tissue sarcomas of the extremities or body wall. Patients and Methods: Twenty-seven patients with radiographically resectable intermediate- or high-grade soft tissue sarcomas were treated. Preoperative external-beam radiation was administered in 25 2-Gy fractions (total dose, 50 Gy). Concurrent continuous-infusion doxorubicin was administered by an initial bolus (4 mg/m2) and subsequent 4-day continuous infusion (12.5, 15.0, 17.5, or 20.0 mg/m2/wk). Radiographic restaging was performed 4 to 7 weeks after chemoradiation, and patients with localized disease underwent surgical resection. Results: Chemoradiation was completed as an outpatient procedure in 25 patients (93{\%}). The maximum-tolerated dose of continuous-infusion doxorubicin combined with standard preoperative radiation was 17.5 mg/m2/wk; at this dose level, seven (30{\%}) of 23 patients had grade 3 dermatologic toxicity. Macroscopically complete resection (R0 or R1) was performed in all 26 patients who underwent surgery. Among 22 patients who were treated with doxorubicin 17.5/mg/m2/wk with concurrent radiation and subsequent surgery, 11 patients (50{\%}) had 90{\%} or greater tumor necrosis, including two patients who had complete pathologic responses. Conclusion: Preoperative doxorubicin-based chemoradiation appears safe and feasible. The maximum-tolerated dose of continuous-infusion doxorubicin with standard preoperative radiation was 17.5 mg/m2/wk. Pathologic response rates with this regimen are encouraging.",
author = "Pisters, {Peter W T} and Patel, {Shreyaskumar R.} and Prieto, {Victor G.} and Thall, {Peter F.} and Lewis, {Valerae O.} and Feig, {Barry W.} and Hunt, {Kelly K.} and Yasko, {Alan W.} and Lin, {Patrick P.} and Jacobson, {Marc G.} and Burgess, {Michael A.} and Pollock, {Raphael E.} and Zagars, {Gunar K.} and Benjamin, {Robert S.} and Matthew Ballo",
year = "2004",
month = "12",
day = "1",
doi = "10.1200/JCO.2004.01.040",
language = "English (US)",
volume = "22",
pages = "3375--3380",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "16",

}

TY - JOUR

T1 - Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas

AU - Pisters, Peter W T

AU - Patel, Shreyaskumar R.

AU - Prieto, Victor G.

AU - Thall, Peter F.

AU - Lewis, Valerae O.

AU - Feig, Barry W.

AU - Hunt, Kelly K.

AU - Yasko, Alan W.

AU - Lin, Patrick P.

AU - Jacobson, Marc G.

AU - Burgess, Michael A.

AU - Pollock, Raphael E.

AU - Zagars, Gunar K.

AU - Benjamin, Robert S.

AU - Ballo, Matthew

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Purpose: The primary objective of this phase I trial was to define the maximum-tolerated dose of continuous-infusion doxorubicin administered with standard preoperative radiation for patients with localized, potentially resectable soft tissue sarcomas of the extremities or body wall. Patients and Methods: Twenty-seven patients with radiographically resectable intermediate- or high-grade soft tissue sarcomas were treated. Preoperative external-beam radiation was administered in 25 2-Gy fractions (total dose, 50 Gy). Concurrent continuous-infusion doxorubicin was administered by an initial bolus (4 mg/m2) and subsequent 4-day continuous infusion (12.5, 15.0, 17.5, or 20.0 mg/m2/wk). Radiographic restaging was performed 4 to 7 weeks after chemoradiation, and patients with localized disease underwent surgical resection. Results: Chemoradiation was completed as an outpatient procedure in 25 patients (93%). The maximum-tolerated dose of continuous-infusion doxorubicin combined with standard preoperative radiation was 17.5 mg/m2/wk; at this dose level, seven (30%) of 23 patients had grade 3 dermatologic toxicity. Macroscopically complete resection (R0 or R1) was performed in all 26 patients who underwent surgery. Among 22 patients who were treated with doxorubicin 17.5/mg/m2/wk with concurrent radiation and subsequent surgery, 11 patients (50%) had 90% or greater tumor necrosis, including two patients who had complete pathologic responses. Conclusion: Preoperative doxorubicin-based chemoradiation appears safe and feasible. The maximum-tolerated dose of continuous-infusion doxorubicin with standard preoperative radiation was 17.5 mg/m2/wk. Pathologic response rates with this regimen are encouraging.

AB - Purpose: The primary objective of this phase I trial was to define the maximum-tolerated dose of continuous-infusion doxorubicin administered with standard preoperative radiation for patients with localized, potentially resectable soft tissue sarcomas of the extremities or body wall. Patients and Methods: Twenty-seven patients with radiographically resectable intermediate- or high-grade soft tissue sarcomas were treated. Preoperative external-beam radiation was administered in 25 2-Gy fractions (total dose, 50 Gy). Concurrent continuous-infusion doxorubicin was administered by an initial bolus (4 mg/m2) and subsequent 4-day continuous infusion (12.5, 15.0, 17.5, or 20.0 mg/m2/wk). Radiographic restaging was performed 4 to 7 weeks after chemoradiation, and patients with localized disease underwent surgical resection. Results: Chemoradiation was completed as an outpatient procedure in 25 patients (93%). The maximum-tolerated dose of continuous-infusion doxorubicin combined with standard preoperative radiation was 17.5 mg/m2/wk; at this dose level, seven (30%) of 23 patients had grade 3 dermatologic toxicity. Macroscopically complete resection (R0 or R1) was performed in all 26 patients who underwent surgery. Among 22 patients who were treated with doxorubicin 17.5/mg/m2/wk with concurrent radiation and subsequent surgery, 11 patients (50%) had 90% or greater tumor necrosis, including two patients who had complete pathologic responses. Conclusion: Preoperative doxorubicin-based chemoradiation appears safe and feasible. The maximum-tolerated dose of continuous-infusion doxorubicin with standard preoperative radiation was 17.5 mg/m2/wk. Pathologic response rates with this regimen are encouraging.

UR - http://www.scopus.com/inward/record.url?scp=4344632232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344632232&partnerID=8YFLogxK

U2 - 10.1200/JCO.2004.01.040

DO - 10.1200/JCO.2004.01.040

M3 - Article

C2 - 15310783

AN - SCOPUS:4344632232

VL - 22

SP - 3375

EP - 3380

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 16

ER -